According to Pulmatrix's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.609547. At the end of 2023 the company had a P/S ratio of 0.9308.
Year | P/S ratio | Change |
---|---|---|
2023 | 0.9308 | -59.98% |
2022 | 2.33 | -51.16% |
2021 | 4.76 | 46.94% |
2020 | 3.24 | 49.08% |
2019 | 2.17 | -97.19% |
2018 | 77.4 | -12.62% |
2017 | 88.6 | 751.78% |
2016 | 10.4 | -81.59% |
2015 | 56.5 | |
2014 | N/A |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Pieris Pharmaceuticals PIRS | 0.2767 | -54.61% | ๐บ๐ธ USA |
OPKO Health
OPK | 1.12 | 84.47% | ๐บ๐ธ USA |
Blueprint Medicines
BPMC | 23.6 | 3,778.54% | ๐บ๐ธ USA |